Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure by Oliveira, Rudolf K. F. et al.
Research Article
Functional impact of exercise pulmonary hypertension in
patients with borderline resting pulmonary arterial pressure
Rudolf K. F. Oliveira1,2,3, Mariana Faria-Urbina1,2, Bradley A. Maron4,5, Mario Santos6,
Aaron B. Waxman1,2 and David M. Systrom1,2
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;
2Heart & Vascular Center, Brigham and Women’s Hospital, Boston, MA, USA; 3Division of Respiratory Diseases, Department of Medicine, Federal University of São
Paulo (UNIFESP), São Paulo, SP, Brazil; 4Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School,
Boston, MA, USA; 5Veterans Affairs Boston Healthcare System, Boston, MA, USA; 6Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D
Unit, Faculty of Medicine, University of Porto, Portugal
Abstract
Borderline resting mean pulmonary arterial pressure (mPAP) is associated with adverse outcomes and affects the exercise pul-
monary vascular response. However, the pathophysiological mechanisms underlying exertional intolerance in borderline mPAP
remain incompletely characterized. In the current study, we sought to evaluate the prevalence and functional impact of exercise
pulmonary hypertension (ePH) across a spectrum of resting mPAP’s in consecutive patients with contemporary resting right heart
catheterization (RHC) and invasive cardiopulmonary exercise testing. Patients with resting mPAP <25 mmHg and pulmonary
arterial wedge pressure 15 mmHg (n¼ 312) were stratified by mPAP< 13, 13–16, 17–20, and 21–24 mmHg. Those with ePH
(n¼ 35) were compared with resting precapillary pulmonary hypertension (rPH; n¼ 16) and to those with normal hemodynamics
(non-PH; n¼ 224). ePH prevalence was 6%, 8%, and 27% for resting mPAP 13–16, 17–20, and 21–24 mmHg, respectively. Within
each of these resting mPAP epochs, ePH negatively impacted exercise capacity compared with non-PH (peak oxygen uptake
70 16% versus 92 19% predicted, P< 0.01; 72 13% versus 86 17% predicted, P< 0.05; and 64 15% versus 82 19%
predicted, P< 0.001, respectively). Overall, ePH and rPH had similar functional limitation (peak oxygen uptake 67 15% versus
68 17% predicted, P> 0.05) and similar underlying mechanisms of exercise intolerance compared with non-PH (peak oxygen
delivery 1868 599 mL/min versus 1756 720 mL/min versus 2482 875 mL/min, respectively; P< 0.05), associated with chron-
otropic incompetence, increased right ventricular afterload and signs of right ventricular/pulmonary vascular uncoupling. In con-
clusion, ePH is most frequently found in borderline mPAP, reducing exercise capacity in a manner similar to rPH. When borderline
mPAP is identified at RHC, evaluation of the pulmonary circulation under the stress of exercise is warranted.
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Introduction
Pulmonary hypertension (PH) is currently defined by resting
mean pulmonary arterial pressure (mPAP) 25mmHg
during a supine right heart catheterization (RHC).1
However, the normal resting mPAP value is known to be
of 14 3mmHg and the upper limit of normal is approxi-
mately 20mmHg.2 Consequently, a substantial number of
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patients have abnormal resting mPAP values, though within
the non-diagnostic PH range.
There is growing evidence that borderline mPAP
(21–24mmHg) is associated with worse long-term outcomes.
Recently, Maron et al. showed in a large heterogeneous
population that resting mPAP 19–24mmHg is associated
with increased risk for hospitalization and mortality.3
Similarly, Kovacs et al. reported resting mPAP
21–24mmHg to be associated with decreased exercise cap-
acity and decreased survival.4 Furthermore, in patients with
known risk factors for pulmonary vascular disease such as
systemic sclerosis, several studies have demonstrated that
borderline mPAP might be a unique clinical phenotype
with associated worse prognosis.5–7
Similar to resting borderline mPAP, recent evidence sug-
gests pre-capillary PH diagnosed during exercise (ePH) is a
clinically relevant condition that is associated with symptoms,
impacts exercise capacity and outcomes, and may progress to
resting PH and might reflect an early (and likely more treat-
able) stage of established PH.8–15 Additionally, recent work
from Lau et al. suggests ePH occurrence is high in borderline
resting mPAP,16 pointing to the possible close association
between these two conditions. However, the pathophysiologic
link between borderline mPAP and ePH and the resultant
functional impact of ePH in borderline mPAP remains
incompletely characterized.
In the current study, we sought to evaluate the prevalence
and functional implications of ePH across a spectrum of
resting mPAP currently considered to be normal, including
borderline mPAP, and to contrast ePH pathophysiological
implications to those of resting precapillary pulmonary
hypertension (rPH). We hypothesized ePH occurrence
increases as a function of higher resting mPAP values,
impacting exercise capacity in a manner similar to rPH.
Methods
We analyzed retrospectively 723 consecutive patients
referred to the Brigham and Women’s Hospital Dyspnea
Center over a 5.5-year period (from January 2012 until
June 2016) with suspected PH who underwent resting
supine RHC followed by an upright symptom-limited inva-
sive cardiopulmonary exercise testing (iCPET) as part of
their clinically indicated evaluation for unexplained exer-
tional intolerance.17 The study protocol was approved by
the Partners Human Research Committee (2011P000272).
According to resting supine RHC, patients were classified
in two groups: those with mPAP< 25mmHg and pulmon-
ary arterial wedge pressure (PAWP) 15mmHg; and those
with mPAP 25mmHg and/or PAWP> 15mmHg (Fig. 1).
For the primary analysis, and in order to evaluate the preva-
lence and functional implications of ePH, as a function of
increasing resting mPAP at RHC, patients with
mPAP< 25mmHg and PAWP 15mmHg were divided in
four subgroups according to regular increasing resting
mPAP intervals (<13mmHg, 13–16mmHg, 17–20mmHg,
Fig. 1. Study flow diagram.
PH, pulmonary hypertension; iCPET, invasive cardiopulmonary exercise testing; RHC, right heart catheterization; mPAP, mean pulmonary arterial
pressure; PAWP, pulmonary arterial wedge pressure; HFrEF, heart failure with reduced ejection fraction; PVR, pulmonary vascular resistance;
LHD, left heart disease; non-PH, normal resting/exercise pulmonary hemodynamics; ePH, exercise pulmonary hypertension; rPH, resting
precapillary pulmonary hypertension.
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and 21–24mmHg) (Fig. 1a). For the secondary analysis, and
to evaluate ePH pathophysiological implications in relation
to patients with resting established disease, ePH iCPET
results were contrasted to those with rPH and those
with normal resting/exercise pulmonary hemodynamics
(non-PH) (Fig. 1b).
Exclusion criteria included: (1) anemia defined by hemo-
globin concentration <10 g.dL1; (2) left heart disease
(LHD) defined by moderate/severe mitral and/or aortic
valvular disease or left ventricular ejection fraction <0.5 at
resting echocardiography, or postcapillary PH identified by
mPAP 25mmHg and PAWP> 15mmHg at resting RHC
or PAWP 15mmHg at rest but abnormally elevated
during exercise associated with a normal peak pulmonary
vascular resistance (PVR) for the patient’s age (i.e. peak
PAWP> 19mmHg and peak PVR 1.35 WU for patients
aged 50 years or PAWP> 17mmHg and peak PVR 2.10
WU for patients aged >50 years);18 (3) pulmonary mechan-
ical limitation to exercise defined by ventilatory reserve at
the anaerobic threshold 0.70;19 (4) submaximal cardiopul-
monary exercise testing defined by peak respiratory
exchange ratio (RER) <1.05 and peak heart rate <85%
predicted and peak mixed-venous partial pressure of
oxygen <27mmHg;20 and (5) incomplete exercise
hemodynamics.
Baseline demographics, anthropometrics, co-morbidities,
and contemporary pulmonary function testing and resting
echocardiography were reviewed. A relevant lung disease
was defined by the forced expiratory volume in the first
second divided by forced vital capacity (FEV1/FVC)
<70% predicted associated with FEV1 <60% predicted,
or a radiologic diagnosis of lung fibrosis associated with a
FVC <70% predicted.21
Pulmonary hypertension definitions
ePH was defined by age-specific exercise pulmonary hemo-
dynamic criteria for maximum upright exercise as follows:
(1) peak mPAP> 30mmHg and peak PVR> 1.34 WU for
patients aged 50 years; or (2) peak mPAP> 33mmHg and
peak PVR> 2.10 WU for patients aged> 50 years.18 rPH
was defined by resting supine RHC as mPAP 25mmHg
and PAWP 15mmHg and PVR> 3 WU.22
Hemodynamic measurements
Our RHC and iCPET methods have been described in pre-
vious studies14,17,18 and is its technical aspects have been
reported in detail elsewhere.23 Briefly, RHC was performed
in the supine position with a pulmonary arterial catheter
(Edwards Lifesciences, Irvine, CA, USA) inserted percutan-
eously via the internal jugular vein and a concurrent cath-
eter placed via the radial artery following a negative Allen’s
test. Cardiac output (CO) at resting RHC was calculated
using Fick’s method and an estimated oxygen consumption
(VO2).
With patients breathing room air, a symptom-limited
incremental CPET was next performed using an upright
cycle ergometer and a breath-by-breath metabolic cart
(ULTIMA CPX; Medical Graphics Corporation, St Paul,
MN, USA). Pulmonary and systemic hemodynamics were
continuously and simultaneously monitored during exercise
(Xper Cardio Physiomonitoring System; Philips, Melborne,
FL, USA). Pulmonary pressures were recorded at the end of
a passive exhalation;23 when respirophasic changes per-
sisted, an electronic average over three respiratory cycles
was used.24 Arterial and mixed venous blood gases and
pH were collected during each minute of exercise, and arter-
ial-mixed venous oxygen content difference (Ca-vO2) was
calculated. By the Fick principle and using a simultaneously
measured VO2, minute per minute CO was than obtained
during exercise. Oxygen delivery (DO2) was calculated
multiplying CO by the arterial oxygen content (CaO2).
Total pulmonary vascular resistance (TPR) and PVR
were calculated by mPAP/CO and mPAP–PAWP/CO,
respectively, and expressed as Wood units (WU).
Pulmonary vascular compliance (PVC) was calculated by:
stroke volume/systolic–diastolic PAP and expressed as mL/
mmHg. Right ventricular stroke work index (RVSWI) was
calculated by: (1.25 mPAP–right atrial pressure stroke
volume index 0.0136)25–27 and expressed as g/m/m2.
Statistical analysis
Unless otherwise stated, values are presented as mean and
standard deviation or median and interquartile range.
Group comparisons were performed using Chi-squared,
Fisher’s exact tests, t-test, or Mann–Whitney U-test as
appropriate. One-way ANOVA with Tukey’s post hoc ana-
lysis was used when comparing more than two groups.
Receiver operating characteristic (ROC) curve analyses
were derived for resting pulmonary hemodynamics while
accounting for the presence or absence of ePH. P< 0.05
was considered significant. The statistical analyses were per-
formed using SPSS software, version 19 (IBM Company,
Armonk, NY, USA).
Results
Of the 723 iCPET reports analyzed, 271 (37%) had resting
supine mPAP 25mmHg and/or PAWP> 15mmHg and
452 (63%) had mPAP< 25mmHg and PAWP 15mmHg
at RHC (Fig. 1). For the primary analysis (Fig. 1a), 140
patients with mPAP< 25mmHg and PAWP 15mmHg
were excluded due to anemia, echocardiographic abnormal-
ities, pulmonary mechanical limitation to exercise, submaxi-
mum exercise test, and/or incomplete data. For the secondary
analysis (Fig. 1b), 255 patients with mPAP 25mmHg and/
or PAWP> 15mmHgwere excluded based on RHC (elevated
PAWP or elevated mPAP with normal PVR) or iCPET data
(rPH with anemia, pulmonary limit, submaximum exercise
test, and/or incomplete exercise hemodynamics), and 53
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patients withmPAP< 25mmHgand PAWP 15mmHgwere
excluded due to LHD diagnosed only during exercise.
Resting mPAP< 13 versus 13–16 versus 17–20
versus 21–24 mmHg
In total, 312 patients with mPAP< 25mmHg and
PAWP 15mmHg were analyzed. Twenty-seven patients
had mPAP< 13mmHg, 96 mPAP 13–16mmHg, 115 mPAP
17–20mmHg, and 74 mPAP 21–24mmHg (Fig. 1a). Their
resting mPAP distribution is presented in the online supple-
mentary material (Fig. S1).
Age, body mass index (BMI), and the presence of co-
morbidities increased as a function of higher resting
mPAP values and a mPAP within the borderline range
(21–24mmHg) was significantly associated with older age
and elevated BMI. At RHC, there was progressively
higher PVR and TPR and lower PVC as a function of
higher mPAPs. Their baseline characteristics and RHC
data are summarized in Table 1.
During iCPET, higher resting mPAP values were asso-
ciated with decreased exercise capacity, as measured by peak
VO2 (Table 2). Also, decreased peak CaO2 and decreased
peak DO2 were observed in borderline mPAP. Exercise
hemodynamics additionally revealed decreased peak CO
and increased peak right atrial pressure, peak TPR, and
peak PVR in patients with resting borderline mPAP
(Table 2).
Based on the aforementioned exercise hemodynamic cri-
teria, ePH occurred in 6% (6 out of 96) of patients with
mPAP 13–16mmHg, 8% (9 out of 115) of patients with
mPAP 17–20mmHg and 27% (20 out of 74) of those with
mPAP 21–24mmHg (Fig. 2).
ePH versus rPH versus non-PH
In total, 35 ePH, 16 rPH, and 224 non-PH patients were
analyzed (Fig. 1b). Compared with non-PH, ePH had
higher resting mPAP (20 3mmHg versus 17 3mmHg,
P< 0.05) and PVR (2.1 0.8 WU versus 1.3 0.5 WU,
P< 0.05) and lower PVC (4.3 1.6mL/mmHg versus
6.2 2.1mL/mmHg, P< 0.05) at RHC. rPH had resting
mPAP of 36 11mmHg, PAWP 10 3mmHg, TPG
27 10mmHg, PVR 5.7 2.8 WU at RHC. rPH and ePH
tended to be older compared with non-PH (62 11 versus
59 16 versus 53 16, P¼ 0.02, respectively) and had more
co-morbidities such as systemic hypertension, connective
tissue disease, diabetes mellitus, and history of pulmonary
embolism. Detailed baseline characteristics and RHC data
for rPH, ePH, and non-PH are presented in the online sup-
plementary material (Table S1).
Patients with ePH had elevated mPAP/CO slopes com-
pared with non-PH across the different mPAP ranges
(Fig. 3), and within each resting mPAP epoch, the develop-
ment of ePH was associated with a significantly reduced
peak VO2 as a % predicted compared with non-PH (Fig. 4).
In the aggregate, ePH and rPH had similarly reduced
exercise capacity compared with non-PH as shown by
their reduced peak VO2, which in turn was associated with
decreased peak CaO2, peak CO, and peak DO2, and indices
of decreased right ventricular function and increased right
ventricular and pulmonary vascular load (Table 3). ePH and
rPH also showed chronotropic incompetence at peak exer-
cise (Table 3). In ePH, chronotropic incompetence occurred
predominately in patients aged> 50 years (Table S2) and
irrespective of the use of beta-adrenergic receptor blockers
(Table S3).
rPH additionally had a reduced peak Ca-vO2 (Table 3).
Peak alveolar-arterial oxygen tension difference was elevated
in rPH and ePH compared with non-PH (64 14mmHg
versus 35 20mmHg versus 17 16mmHg, respectively;
P< 0.05). Arterial oxygen saturation was reduced in rPH
and ePH compared with non-PH (85 6% versus 93 4%
versus 97 5%, respectively; P< 0.05).
The analysis of minute per minute PVR versus PVC rela-
tionship during exercise (n¼ 2129 individual data points
obtained from the 224 non-PH patients, n¼ 294 from the
35 ePH and n¼ 115 from the 16 rPH) revealed that ePH
pulmonary hemodynamic response to exercise was inter-
mediate between non-PH and rPH (Fig. 5a). Additionally,
by the logarithmic transformation of PVR and PVC
(Fig. 5b), a progressive downward-leftward change of
PVR versus PVC relation was observed for ePH compared
with non-PH during exercise, reflecting the dynamic pul-
monary vascular responses that led ePH to be an intermedi-
ate pulmonary hemodynamic stage between normality and
established disease.
RHC ePH predictors
By ROC analysis, resting supine mPAP, PVR, and PVC
provided prediction information about the presence or
absence of ePH (AUC¼ 0.76, 95% CI¼ 0.68–0.85,
P< 0.01; AUC¼ 0.78, 95% CI¼ 0.69–0.88, P< 0.01; and
AUC¼ 0.76, 95% CI¼ 0.67–0.84, P< 0.01, respectively).
Their optimal cutoff values to separate ePH from non-PH
were 19mmHg for resting mPAP, 1.6 WU for resting PVR,
and 4.6mL/mmHg for resting PVC. Of the ePH patients,
83% had a mPAP 19mmHg and/or a PVR 1.6 WU at
resting supine RHC.
Discussion
In the present study, we demonstrate that the prevalence of
ePH increases as a function of higher resting mPAP values
and is found in 27% of the patients with borderline mPAP
(21–24mmHg). When present, ePH substantively affects
exercise capacity regardless of the resting mPAP range and
the functional impact of ePH is similar than that observed in
rPH. ePH and rPH have shared mechanisms of exercise
intolerance, suggesting that ePH represents an early patho-
physiological stage of rPH. The current findings indicate
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Participants 27 96 115 74
Age (years) 49 11 51 16 56 16 62 13*yz
Women (n (%)) 17 (63) 70 (73) 65 (67) 39 (53)
BMI (kg/m2) 26.3 5.8 26.6 6.4 29.1 6.5* 30.1 6.2*y
Hemoglobin (g/dL) 14.3 1.4 14.0 1.5 14.2 1.6 13.7 1.5
Co-morbidities (n (%))
None 17 (63) 48 (50) 41 (36) 19 (26)
Hypertension 4 (15) 28 (29) 50 (43) 38 (51)
Connective tissue disease 2 (7) 6 (6) 11 (10) 12 (16)
Diabetes mellitus 1 (4) 3 (3) 13 (11) 9 (12)
Lung disease 0 2 (2) 5 (4) 6 (8)
Smokers 0 3 (3) 4 (3) 1 (1)
History of pulmonary embolism 0 6 (6) 8 (7) 7 (9)
Medications (n (%))
Diuretics 4 (15) 10 (10) 23 (20) 16 (22)
ACE inhibitor or ARB 6 (22) 26 (27) 44 (38) 29 (39)
Beta-adrenergic receptor blocker 2 (7) 11 (11) 26 (23) 19 (26)
Calcium channel blocker 2 (7) 8 (8) 13 (11) 12 (16)
Pulmonary function testing
FEV1 (% predicted) 97 13 94 16 87 19*
y 82 18*y
FVC (% predicted) 98 13 94 17 87 19*y 83 17*y
FEV1/FVC (% predicted) 99 5 100 8 99 10 98 12
Echocardiography
LA AP diameter (mm) 35 4 35 5 36 5 38 6*y
LVEF (%) 63 6 62 4 62 4 62 5
TRV (m/s) 2.2 0.3 2.3 0.3 2.4 0.4* 2.5 0.3*y
Estimated sPAP (mmHg) 22 9 23 5 27 7* 28 7*y
Right heart catheterization
RA (mmHg) 4 2 5 2 7 2*y 7 3*y
mPAP (mmHg) 11 1 15 1* 18 1*y 22 1*yz
PAWP (mmHg) 6 2 9 2* 11 2*y 13 3*yz
TPG (mmHg) 5 2 6 2 7 3*y 9 3*yz
CO (L/min) 4.8 1.0 5.4 1.1 5.4 1.1 5.5 1.3
CI (L/min/m2) 2.7 0.6 2.9 0.6 2.8 0.5 2.8 0.6
TPR (WU) 2.5 0.7 2.9 0.6 3.5 0.7*y 4.3 1.2*yz
PVR (WU) 1.0 0.4 1.1 0.4 1.4 0.6*y 1.8 0.7*yz
PVC (mL/mmHg) 7.3 2.4 6.5 2.2 5.8 1.9* 4.7 1.9*y
Data are presented as n, n (%), or mean standard deviation.
*P< 0.05 compared with mPAP< 13 mmHg.
yP< 0.05 compared with mPAP 13–16 mmHg.
zP< 0.05 compared with mPAP 17–20 mmHg.
BMI, body mass index; ACE, angiotensin-converting- enzyme; ARB, angiotensin II receptor antagonist; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; LA AP, left atrium anteroposterior; LVEF, left ventricular ejection fraction; TRV, tricuspid regurgitant jet velocity; sPAP, systolic pulmonary arterial pressure;
RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; TPG, transpulmonary gradient; CO, cardiac output;
CI, cardiac index; TPR, total pulmonary vascular resistance; PVR, pulmonary vascular resistance; PVC, pulmonary vascular compliance.
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that the identification of borderline mPAP at RHC should
encourage the evaluation of the pulmonary circulation
under the stress of exercise to uncover clinically relevant
early pulmonary vascular disease.
Prevalence of ePH in borderline mPAP
Our results reveal that ePH prevalence is elevated in border-
line mPAP (Fig. 2), but lower than that previously
reported.16 Lau et al.16 recently described a 65% prevalence
of pre-capillary PH during exercise for mPAP 21–
24mmHg;16 however, the aforementioned study evaluated
patients from a PH Referral Center with an elevated preva-
lence of PH risk factors.16 Conversely, the present study
evaluated patients from a Dyspnea Center, which encom-
pass a heterogenous patient population with unexplained
exertional intolerance. To our knowledge, the current
study is the largest to date to evaluate directly measured
invasive exercise hemodynamics as a function of increasing
resting mPAP values in a general population undergoing










Participants 27 96 115 74
Maximum work rate (W) 137 50 134 54 123 49 102 42*yz
Peak VO2 (% predicted) 90 21 91 22 83 18*
y 75 19*yz
Peak VO2 (mL/kg/min) 23.6 8.1 22.5 8.5 19.2 6.4*
y 15.7 5.3*yz
VO2 at AT (% VO2MAX predicted) 49 12 51 17 45 10
y 43 13y
Peak heart rate (bpm) 151 18 151 25 142 26y 129 27*yz
Peak heart rate (% predicted) 88 11 89 11 86 12 80 14*yz
Peak RER 1.19 0.12 1.14 0.12 1.14 0.13 1.12 0.11
Peak VE/MVV 64 16 60 16 66 21 64 17
VE/VCO2 slope 32 8 31 6 32 8 36 10
yz
Peak PA aO2 (mmHg) 11 11 17 12 18 19 28 19*
yz
Peak SaO2 (%) 98 1 97 2 96 7 95 4
Peak CaO2 (mL/dL) 19.5 1.9 19.1 2.4 19.5 2.3 18.3 2.2
z
Peak Ca-vO2 (mL/dL) 13.2 1.8 12.6 2.0 12.7 2.0 12.2 2.0
Peak DO2 (mL/min) 2535 884 2541 930 2490 871 2012 707*
yz
Peak DO2 (mL/kg/min) 34.7 11.4 34.2 12.4 29.8 9.8
y 23.5 9.8*yz
Exercise hemodynamics
Peak RAP (mmHg 5 4 6 4 7 5 9 5*yz
Peak mPAP (mmHg) 23 6 26 7 29 8*y 34 8*yz
Peak PAWP (mmHg) 10 4 12 5 14 6* 16 6*y
Peak TPG (mmHg) 13 4 14 5 16 6 19 7*yz
Peak CO (L/min) 12.8 3.7 13.1 3.9 12.7 3.9 10.9 3.3yz
Peak CI (L/min/m2) 7.0 1.8 7.0 1.9 6.4 1.7y 5.5 1.5*yz
Peak SV (mL) 85 23 88 25 90 24 86 20
Peak SVI (mL/m2) 47 12 47 11 46 10 43 7y
Peak TPR (WU) 1.9 0.5 2.2 0.8 2.5 0.9* 3.5 1.5*yz
Peak PVR (WU) 1.1 0.4 1.2 0.6 1.3 0.6 1.8 0.9*yz
Peak PVC (mL/mmHg) 3.6 1.4 3.6 1.6 3.3 1.4 3.1 1.2
Peak RVSWI (g/m/m2) 15.4 6.6 17.4 6.7 18.6 6.8 19.8 6.6*
Data are presented as n or mean standard deviation.
*P< 0.05 compared with mPAP< 13 mmHg.
yP< 0.05 compared with mPAP 13–16 mmHg.
zP< 0.05 compared with mPAP 17–20 mmHg.
VO2, oxygen uptake; VO2MAX, maximal oxygen uptake; AT, anaerobic threshold; RER, respiratory exchange ratio; VE/MVV, ventilatory reserve; VE/VCO2, venti-
latory equivalent for carbon dioxide; PAaO2, alveolar–arterial oxygen tension difference; SaO2, arterial oxygen saturation; CaO2, arterial oxygen content; Ca-vO2,
arterial–mixed venous oxygen content difference; DO2, oxygen delivery; RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary
arterial wedge pressure; TPG, transpulmonary gradient; CO, cardiac output; CI, cardiac index; SV, stroke volume; SVI, stroke volume index; TPR, total pulmonary
vascular resistance; PVR, pulmonary vascular resistance; PVC, pulmonary vascular compliance; RVSWI, right ventricular stroke work index.
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dyspnea investigation and therefore, might more accurately
reflect ePH real-life prevalence across different resting
mPAP ranges. Despite differences in ePH prevalence, our
findings and those of Lau et al.16 agree that increasing rest-
ing mPAP values are associated with increased ePH occur-
rence, reinforcing the notion that borderline mPAP should
be considered a population at risk for ePH development.
We additionally observed that increasing resting mPAP
values were associated with increasing age, BMI, and co-
morbidities rate (Table 1), which were followed by progres-
sively abnormal exercise pulmonary hemodynamics
(Table 2). These findings are in accord with those of
others3,4 and likely reflect the association between the pres-
ence of co-morbidities and PH risk factors and the develop-
ment of abnormal pulmonary vascular responses during
exercise.
Functional impact of ePH in borderline mPAP
A key finding of the current study is that regardless of the
resting mPAP range, the development of ePH is associated
with a reduced exercise capacity (Fig. 4). This finding high-
lights the additive value of exercise hemodynamics to detect
early disease. Additionally, using simultaneously measured
Fig. 3. Mean pulmonary arterial pressure to cardiac output (mPAP/CO) slope from rest upright to peak upright according to the right heart
catheterization mPAP. mPAP< 13 mmHg (a), mPAP 13–16 mmHg (b), mPAP 17–20 mmHg (c), and mPAP 21–24 mmHg (d). Slope values are
presented as median [interquartile range].
non-PH, normal resting/exercise pulmonary hemodynamics; ePH, exercise pulmonary hypertension.
*P< 0.05 compared with non-PH.
Fig. 2. Prevalence of exercise pulmonary hypertension (ePH) according to the resting mean pulmonary arterial pressure (mPAP) at right heart
catheterization (RHC).
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maximum incremental VO2 (and its indirect determin-
ants) and invasive pulmonary hemodynamics, we demon-
strate for the first time that ePH and rPH have similar
mechanisms underlying exercise intolerance, specifically,
impaired DO2 and indices of increased right ventricular
and pulmonary vascular load and chronotropic incompe-
tence (Table 3).
The decreased peak DO2 was associated with concurrent
reduction of peak CaO2. and peak CO for both ePH and
rPH. While the reduced peak CaO2 reflects the known
impact of pulmonary vascular disease on the oxygen diffu-
sion through the vascular bed,28 the decreased peak CO is
likely a result of increased right ventricular afterload (seen
by abnormal peak PVR and peak PVC) and right ventricu-
lar/pulmonary vascular uncoupling (suggested by the ele-
vated peak right atrial pressure and RVSWI) in both ePH
and rPH (Table 3).
Right ventricular maladaptation to increased pulmonary
vascular load is a known phenomenon in pulmonary arterial
hypertention.29–31 In the current study, we found signs of
dynamic (only during exercise) right ventricular/pulmonary
vascular uncoupling in ePH associated with elevated right
heart afterload and right ventricular work, in a similar
manner to that found for rPH (Table 3). Ventriculoarterial
uncoupling is associated with worse prognosis in established
PH;32 therefore, we speculate that this very similar patho-
physiology we have observed in ePH may account for their
adverse outcomes recently described by others.15 However,
the present study was cross-sectional by design and future
longitudinal studies are needed to address the underlying
link between ePH and long-term outcomes.
ePH and rPH also had chronotropic incompetence that
contributed to their reduced exercise capacity (Table 3). In
ePH, this occurred largely in participants aged >50 years
(Table S2) and was not strictly related to medication use
(Table S3). In resting established PH, chronotropic incom-
petence has been associated with right heart failure and
autonomic imbalance.33–36 Additionally, recent data suggest
that in post-pulmonary endarterectomy patients with ePH,
chronotropic incompetence might also occur.37 In our study,
the chronotropic incompetence observed in older ePH
patients was accompanied by indices of increased right ven-
tricular work to an increased pulmonary vascular load
(Table S3), suggesting therefore association with disease
severity (i.e. autonomic imbalance due to right ventricular
dysfunction35,36). rPH also had a reduced peripheral oxygen
extraction, as seen by the blunted Ca-vO2 difference at peak
exercise (Table 3), which likely reflect an associated skeletal
muscle dysfunction38,39 and the multifactorial causes of
exercise limitation in rPH.40,41
Taken together, the current findings provide important
insight into the mechanisms of exercise intolerance in early
pulmonary vascular disease. The results confirm previous
non-invasive exercise findings in resting established PH41
and additionally suggest that oxygen delivery is impaired
in the early stages of pulmonary vascular disease (i.e. ePH).
Recently, Kovacs et al. demonstrated that patients with
borderline mPAP have decreased exercise capacity,4 a find-
ing confirmed by the current study (Table 2). However, our
data indicate that patients with borderline mPAP have a
heterogeneous pulmonary vascular response to exercise,
including patients with and without ePH, and that only
Fig. 4. Peak oxygen uptake (VO2) across different resting mean pulmonary arterial pressure (mPAP) values at right heart catheterization.
Data represent the mean SD (error bars).
non-PH, normal resting/exercise pulmonary hemodynamics; ePH, exercise pulmonary hypertension.
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those who develop ePH will suffer a functional limitation
(Fig. 4). Therefore, our data suggest that ePH rather than
borderline mPAP per se more precisely reflects an early
pathophysiological stage of pulmonary vascular disease.
Assuming that pulmonary vascular dysfunction is a pro-
gressive phenomenon and that its late diagnosis is a major
contributor to patient’s poor outcomes,42 considering ePH
(rather than borderline resting mPAP) as an early stage of
pulmonary vascular disease might be of major clinical rele-
vance, potentially allowing early and more effective thera-
peutic interventions that could impact PH natural history.
Predictive value of RHC for ePH
In addition to resting mPAP, other RHC measurements
such as PVR and PVC also provided predictive information
regarding ePH occurrence. This finding is of major clinical
relevance and may provide additional framework for the
identification of subgroups at a higher risk for ePH devel-
opment and should stimulate further investigation.
However, given the just moderate predictive value obtained
from these variables in the current study (AUC¼ 0.76–0.78)
and the substantial variability of pulmonary vascular
responses across different resting RHC patterns, exercise
hemodynamics should remain indispensable for the detec-
tion of early stages of pulmonary vascular dysfunction until
more robust evidence is generated.
Limitations
The study sample was derived from a tertiary dyspnea center
and therefore the generalization of our findings should be
done with caution. Non-PH patients were symptomatic and
our sample reflect a heterogeneous population undergoing
investigation for unexplained exertional intolerance. rPH
and ePH patients also represent a heterogenous population
that included patients with suspected PH of different causes.
However, a subanalysis according to cardiovascular co-mor-
bidities and PH risk factors revealed similar findings com-
pared to those of the entire population (Tables S4 and S5),
indicating that the mechanisms underlying their impaired
exercise capacity are similar and that the hemodynamic pro-
file had a central role influencing exercise intolerance. Our
rPH population was relatively small in sample size due to
the infrequency that participants with established resting
disease undergo iCPET in our center and was older com-
pared to non-PH and ePH, what might have influenced our
rPH exercise hemodynamic findings. Additionally, due to
the nature of the iCPET clinical referrals (i.e. investigation
of unexplained exercise intolerance), rPH was mild in sever-
ity, which likely mitigated the changes during exercise that
would have been seen with more severe disease. However,
rPH were selected based on RHC criteria supported by cur-
rent guidelines22 and represent a well established spectrum
of pulmonary vascular disease.
For the ePH definition, we used age-related mPAP and
PVR thresholds, derived from the study of physiologically
normal participants that underwent an identical upright
maximum incremental cycling exercise protocol to the one
used in the current study.18 This age-specific ePH criteria
addresses one of the major concerns that led to the exclusion
of the ePH definition from the PH guidelines in 2008 (i.e. the
uncertainty of the upper limits of normal for pulmonary
hemodynamics in participants aged >50 years) and
Table 3. Functional and pathophysiological determinants of exercise
pulmonary hypertension (ePH) and resting precapillary pulmonary
hypertension (rPH) during upright invasive cardiopulmonary exercise
testing.
Non-PH ePH rPH
Participants 224 35 16
Exercise capacity
Maximum work rate (W) 129 49 99 43* 77 49*
Peak VO2 (% predicted) 88 19 67 15* 68 17*
Peak VO2 (mL/kg/min) 21.1 7.2 14.7 4.4* 14.3 5.8*
VO2 at AT (% VO2MAX
predicted)
48 12 40 11* 39 11*
Determinants of exercise capacity
Peak CaO2 (mL/dL) 19.3 2.2 18.1 2.4* 16.7 2.0*
Peak CvO2 (mL/dL) 6.6 1.7 6.2 2.1 6.3 1.8
Peak Ca-vO2 (mL/dL) 12.7 1.9 12.0 2.5 10.4 1.8*
y
Peak CO (L/min) 12.8 3.9 10.2 2.7* 10.3 3.4*
Peak CI (L/min/m2) 6.7 1.9 5.3 1.2* 5.6 1.7*
Peak SV (mL) 88 24 82 14 79 22
Peak SVI (mL/m2) 46 10 41 6* 43 10
Peak heart rate (bpm) 147 25 128 28* 131 23*
Peak heart rate
(% predicted)
88 11 78 13* 82 11
Peak DO2 (mL/min) 2482 875 1868 599* 1756 720*
Peak DO2 (mL/kg/min) 32.3 11.1 22.1 6.7* 23.1 10.2*
Pulmonary pressures
Peak mPAP (mmHg) 26 6 40 7* 58 11*y
Peak PAWP (mmHg) 11 4 15 6* 15 7*
Peak TPG (mmHg) 15 5 25 6* 43 10*y
Indices of right ventricular and
pulmonary vascular load
Peak RAP (mmHg) 5 4 10 6* 9 5*
Peak TPR (WU) 2.2 0.7 4.3 1.6* 6.1 2.3*y
Peak PVR (WU) 1.3 0.6 2.5 0.9* 4.6 1.8*y
Peak PVC (mL/mmHg) 3.5 1.4 2.6 1.2* 1.6 0.7*
Peak RVSWI (g/m/m2) 16.9 6.4 22.7 5.6* 36.7 10.9*y
Data are presented as n or mean standard deviation.
*P< 0.05 compared with non-PH.
yP< 0.05 comparing rPH vs. ePH.
VO2, oxygen uptake; VO2MAX, maximal oxygen uptake; AT, anaerobic threshold;
CaO2, arterial oxygen content; CvO2, mixed-venous oxygen content; Ca-vO2,
arterial–mixed venous oxygen content difference; CO, cardiac output; CI, car-
diac index; SV, stroke volume; SVI, stroke volume index; DO2, oxygen delivery;
mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge
pressure; TPG, transpulmonary gradient; RAP, right atrial pressure; TPR, total
pulmonary vascular resistance; PVR, pulmonary vascular resistance; PVC, pul-
monary vascular compliance; RVSWI, right ventricular stroke work index.
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therefore likely decreases the number of false positive/nega-
tive diagnoses of ePH as a function of normal aging. The use
of exercise hemodynamic thresholds determined by age is
supported by additional recent evidence that pulmonary
hemodynamics vary according to age in well-defined
normal participants.43 Nonetheless, there was 92.66% con-
cordance between the ePH definition used in the current
study and the alternative proposed ePH criteria that uses a
peak mPAP> 30mmHg and peak TPR> 3 WU regardless
of age.13
A subanalysis comparing the different ePH criteria is
presented in the online supplementary material (Fig. S2
and Tables S6–S8). Considering peak VO2 as a marker
of the presence/absence of disease, the age-specific ePH
criteria demonstrated better sensitivity for participants
aged 50 years and better specificity for participants
aged >50 years (Table S4). These additional findings rein-
force the potential role of age-specific exercise hemo-
dynamic thresholds to identify clinically relevant
abnormal pulmonary hemodynamic responses to exercise.
However, our ePH criteria has not been externally vali-
dated and therefore further studies are necessary to con-
firm our findings.
Resting RHC CO was calculated using the Fick principle
and an estimated VO2; therefore, resting supine CO-derived
variables should be interpreted with caution. We did not use
high-fidelity catheters to acquired pulmonary hemodynamic
measurements, and more specifically pulmonary pulse pres-
sure, during exercise; therefore, PVC findings should be
carefully interpreted. During iCPET, pulmonary pressures
were either measured through a passive exhalation,23 or
using an electronic average over the respiratory cycle.24
The use of different techniques to measure pulmonary pres-
sures might be considered a confounding factor, but it has
been our observation that the pulmonary vascular pressures
obtained during the passive exhalation technique do not
differ from an average through the respiratory cycle in
patients able to perform both. Finally, we did not directly
measure right ventricular contractile reserve during exercise
and did not evaluate the long-term prognostic implications
of ePH. Therefore, future studies are needed to address these
issues.
Conclusions
The prevalence of ePH increases as a function of higher
resting mPAP values currently considered in the normal
range and is most frequently found in borderline mPAP.
The development of ePH substantively affects exercise cap-
acity regardless of the resting mPAP, and ePH and rPH
share an underlying impaired oxygen delivery, increased
right heart afterload, signs of right ventricular/pulmonary
vascular uncoupling, and chronotropic incompetence that
reduce exercise capacity. The current findings indicate that
in the presence of borderline mPAP at RHC, evaluation of
the pulmonary circulation under the stress of exercise is
warranted to uncover physiologically and clinically relevant
early pulmonary vascular disease.
Fig. 5. Minute per minute relationship between pulmonary vascular resistance (PVR) and pulmonary vascular compliance (PVC) from rest
upright to peak exercise, which included rest, freewheeling and minute per minute incremental PVR and PVC until symptom-limited peak exercise
(a). Minute per minute Log [PVR] – log [PVC] plot (b). n¼ 2129 individual data points obtained from 224 non-PH patients, n¼ 294 from 35 ePH,
and n¼ 115 from 16 rPH patients. non-PH, normal resting/exercise pulmonary hemodynamics; ePH, exercise pulmonary hypertension; rPH,
resting precapillary pulmonary hypertension.
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